Klinkhamer Group | conferences & events
Newsletter 4
11th World Congress on Alternatives and Animal Use in the Life Sciences
Free Live WC11 webinars on 
3Rs in COVID-19 research
25 and 26 August 2020 | 3 PM CET
On 25 and 26 August 2020 at 3 PM CET, WC11 will organize two 1.5 hour webinars on 3Rs in COVID-19 research. On both days, several excellent presentations will highlight innovative model systems to study COVID-19, and will also discuss new strategies for the development of vaccines, therapeutics and diagnostics and much more!
New speaker confirmed!
Tuesday 25 August 2020
Recently announced: 
Dr Penny Hawkins BSc PhD
Head of Research Animals Department, RSPCA (United Kingdom)
Coronavirus research – anything goes?

 Koert Stittelaar, PhD.
 General Manager, Viroclinics Xplore (The Netherlands)
 Animal models and alternatives for COVID-19 research
Wednesday 26 August 2020
Jan Willem van der Laan
Senior Assessor Pharmacology and Toxicology, Medicines Evaluation Board, Chair Safety Working Party CHMP, EMA (The Netherlands)
3Rs and COVID-19 Vaccine Development: Regulatory Aspects
"Development of COVID-19 vaccines is ongoing under pressure. The International Coalition of Medicines Regulatory Authorities (ICMRA) has discussed the potential request of animal data and has confirmed that these data proving efficacy and safety (e.g. with respect to potential disease enhancement) might not be available at the time of clinical trial initiation.
Opportunities to use knowledge accumulated with platform technology might accelerate the development of a COVID-19 vaccine. This platform technology utilized to manufacture a vaccine already licensed, might enable the use of toxicology data from this licensed vaccine obviating the need for specific safety data for the new candidate COVID-19 vaccine.
The potential for vaccine-induced disease enhancement needs further attention, although it is acknowledged that no adequate animal models are available in this respect."
Recently announced: 
Shuibing Chen
Kilts Family Associate Professor, Director of Diabetes Program, Department of Surgery, Weill Cornell Medicine (United States of America)
Human Pluripotent Stem Cell Models for COVID-19 Disease Modeling and Drug Screening
Thomas Hartung
Director CAAT, Johns Hopkins University (United States of America)
COVID-19 – what is in the box of alternative methods?
Already 350+ registrations! Register now.
It is now possible to register for this important and interesting webinar series by clicking the button below.
Is there a role for the 3Rs in COVID-19 research?
In the past few weeks we have asked several people to answer the question: "Is there a role for the 3Rs in COVID-19 research?". Every week we will send you the answers we received from scientists all over the world.
Amy J. Clippinger
President of the People for the Ethical Treatment of Animals International Science Consortium Ltd. (United Kingdom)
“In the race to develop lifesaving vaccines and treatments for COVID-19, many researchers have embraced the 3Rs. For instance, the US Food and Drug Administration has allowed companies to prioritize clinical trials instead of waiting for the results of animal tests that often fail to predict human responses to new drug candidates. Modern non-animal methods, such as 3D reconstructed human respiratory tissue models from MatTek and Epithelix, have taken center stage to study COVID-19 infection and screen for potential treatments. Researchers are also turning to the use of recombinant human antibodies in place of animal-derived antibodies because they are more scientifically robust, have defined sequences, and can be made faster than animal-derived antibodies. For example, in March, YUMAB GmBH announced that it had generated the first human antibodies against the new coronavirus strain, and the company has since confirmed likely therapeutic effects using the patient-derived coronavirus strain SARS-CoV-2. This is just the beginning of the world recognizing that non-animal methods give us our best chance at saving lives quickly and safely. Forward-thinking scientists are seeing this moment as an opportunity to reimagine our approach to science and establish non-animal methods as the gold standard for future research.”
Marcelo Asprea
Chief of Laboratory Animal Care and Experimental Surgery Childrens Hospital Prof. Dr. Juan P. Garrahan (Argentina)
“The COVID19 pandemic, which has surprised humanity, strikes us and makes us quickly consider new paradigms for science. The need to achieve results urgently means that traditional processes must be adapted to this new reality. Precisely this situation leaves us no choice but to take a shortcut on the way to our goal. The 3Rs are not only the future, but they have also been the past and are the present. Many of the trials, which are being carried out searching for new drugs through the use of nanoparticles and vaccines using biological synthetics, are developed under this vision. The need for minimal animal testing and parallel human testing means that technology in alternative methods must achieve perfection. In an unsustainable world, it is very likely that in the future we will have to face new diseases never seen before, so the development of more and better research on 3Rs becomes our present."
Xiaoting Qu
Deputy Secretary General of the Society of Toxicity Testing and Alternative Methods, Chinese Environmental Mutagen Society (China)
“The COVID-19 pandemic posed great challenges to the speed of therapeutics identification and precision medicine. The 3Rs could help to fill the current knowledge and technology gaps, accelerate the discovery and development of drugs as well as the elucidation of the underlying mechanisms. Recent advances in in vitro models like organoid cultures offer a remarkable opportunity and promising tools for understanding of the pathogenesis of COVID-19, speedy identification of drug candidates, and optimization of the cocktail recipes for COVID-19. The 3Rs will also contribute to streamline vaccines production process via removing redundant tests. It is thus expected that the 3Rs will underpin the modern public health management system with profound understandings and effective measures for risk prevention and control."
11th World Congress on Alternatives and Animal Use in the Life Sciences
E. info@wc11maastricht.org
T. +31 (0)43 362 70 08
Follow us on Social Media:
This email was sent to
You received this email because you are registered to the WC11 mailing list.
© 2020 Klinkhamer Group | conferences & events